Celltrion Files Petition for IPR of Genentech’s Trastuzumab Patent

PTAB + IPR

Celltrion has filed a petition for inter partes review (IPR2017-00959) of Genentech’s U.S. Patent 8,591,897.  According to the petition, the patent is directed to methods of treating a sub-type of breast cancer with a regimen that includes trastuzumab.  Trastuzumab is marketed by Genentech under the trade-name Herceptin®.

This petition and other important documents from inter partes review proceedings of biologic patents are posted on our IPR tracker page.

 

Download PDF

Tagged with 

Comments are closed.